Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Paul Capital puts money on Plethora's male health franchise:

This article was originally published in Clinica

Executive Summary

Plethora Solutions is to gain up to $28m in new capital under the terms of a revenue interest financing agreement with the healthcare investment arm of Paul Capital Partners. The funds will be used as working capital to underwrite ongoing phase III clinical programmes in premature ejaculation and erectile dysfunction, as well as to strengthen Plethora's balance sheet, said the London-based company. Plethora will receive $15m on signing of the agreement and a further $10m on the first US sales of Plethora's premature ejaculation product, PSD502. In return, Paul Capital will receive an interest in revenues generated by sales of Plethora's male health products, namely the PSD502 and its erectile dysfunction products PSD503 (still in development stage) and ErecAid, which is marketed by its subsidiary, Timm Medical. The agreement also includes an option for Paul Capital to make an additional $3m equity investment. Plethora's portfolio also includes products for women's health - these are not covered in the agreement.

Advertisement
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT046625

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel